At a glance
CAR-T cell therapy is a treatment in which a patient's own immune cells are genetically reprogrammed in a laboratory to recognise and destroy cancer cells.
T cells (a type of white blood cell that normally fights infection) are collected from the patient's blood, then modified so that each cell carries a new protein on its surface called a chimeric antigen receptor, or CAR. This receptor acts like a lock that fits exactly onto a matching key on the surface of cancer cells. Once infused back into the body, the reprogrammed cells seek out cancer cells bearing that key, attach to them, and kill them. The modified cells also multiply inside the body, so a single infusion can produce millions of cancer-fighting soldiers.
Medical Condition
CAR-T cell therapy is approved for certain blood cancers and lymphomas (cancers of the lymphatic system) that have not responded adequately to standard treatments or that have come back after earlier treatment.
- Diffuse large B-cell lymphoma (DLBCL), a fast-growing type of blood cancer, that has relapsed or not responded to at least two prior treatments
- Follicular lymphoma (a slower-growing lymphoma) in patients who have had multiple relapses
- Mantle cell lymphoma, a rare and aggressive blood cancer
- Acute lymphoblastic leukaemia (ALL), a blood cancer affecting white blood cells, particularly in children, adolescents, and young adults up to the age of 25
- Multiple myeloma (a cancer of plasma cells in the bone marrow) after several other treatments have been tried
- Primary mediastinal B-cell lymphoma in relapsed or refractory cases
CAR-T therapy is not suitable for every patient. Doctors will carefully review medical history, overall health, and organ function before recommending it.
- Active, uncontrolled infection that could be worsened by suppressing the immune system further
- Severely reduced heart, lung, kidney, or liver function that may not tolerate the procedure or the side effects
- Active autoimmune disease (a condition in which the immune system attacks the body's own tissues) that could be dangerously amplified
- Certain types of cancer that do not express the surface markers that CAR-T cells are designed to target
- Patients who cannot commit to the required period of close monitoring after infusion
Risks & Complications
CAR-T cell therapy carries real and sometimes serious risks, and patients are monitored very closely for at least several weeks after the infusion.
- Cytokine release syndrome, or CRS: the most common serious side effect, in which the activated immune cells release a flood of chemical signals called cytokines, causing high fever, low blood pressure, and difficulty breathing. Severity ranges from mild to life-threatening.
- Immune effector cell-associated neurotoxicity syndrome, or ICANS: neurological side effects including confusion, difficulty speaking, tremors, and in severe cases seizures or reduced consciousness
- Prolonged low blood cell counts (cytopenias): the treatment can suppress bone marrow for weeks or months, raising the risk of serious infection, anaemia (low red blood cells causing fatigue), and bleeding
- Serious infections: a weakened immune system makes bacterial, viral, and fungal infections harder to fight, sometimes requiring hospitalisation
- Allergic or infusion reactions during or shortly after the CAR-T cells are given back
- Tumour lysis syndrome: rapid breakdown of cancer cells releases substances into the bloodstream that can stress the kidneys and heart
- Long-term low immunoglobulin levels (B-cell aplasia): because many CAR-T products also destroy healthy B cells (a type of immune cell), patients may need regular immunoglobulin replacement therapy for years
- In rare cases, second cancers arising from the genetic modification process have been reported and are under active study by health regulators
Preparation & Procedure
Preparation for CAR-T therapy spans several weeks and involves both laboratory work and getting the patient's body ready to receive the modified cells.
Before the cell collection, the care team will review all current medications. Blood thinners, certain immunosuppressants (drugs that reduce immune activity), and corticosteroids (anti-inflammatory medicines) may need to be paused or adjusted, because they can interfere with how well the T cells are collected or engineered. Patients are usually advised to stop smoking and avoid alcohol during this period, as both affect immune cell health. Fasting is not typically required for the cell collection itself, but hospital instructions vary and should be followed exactly.
Several tests are done before treatment begins to confirm the patient is suitable and to create a baseline for monitoring.
- Blood tests to check counts of red cells, white cells, and platelets, as well as kidney and liver function
- Heart tests, usually an ECG (electrocardiogram, a recording of heart rhythm) and sometimes an echocardiogram (heart ultrasound)
- Lung function tests in some patients
- Imaging scans, such as PET-CT (a scan combining metabolism imaging with detailed body pictures) to assess the extent of the cancer
- Bone marrow biopsy (removal of a small sample of bone marrow for examination) if the cancer involves the marrow
- Infectious disease screening, including tests for viruses such as HIV and hepatitis
The procedure itself follows a sequence that typically takes several weeks from start to infusion.
- Step 1 - Leukapheresis: the patient is connected to a machine that filters blood, separates out T cells, and returns the rest of the blood to the body. This takes three to five hours and usually does not require a general anaesthetic.
- Step 2 - Laboratory manufacturing: the collected T cells are sent to a specialist laboratory, where they are genetically modified to carry the CAR protein and then multiplied in large numbers. This manufacturing period typically takes two to six weeks.
- Step 3 - Lymphodepletion chemotherapy: a few days before the CAR-T cells are ready, the patient receives a short course of chemotherapy. This temporarily reduces existing immune cells in the body, making room for the new CAR-T cells to expand effectively.
- Step 4 - Rest and monitoring: after lymphodepletion, there is usually a short rest period before infusion.
- Step 5 - CAR-T cell infusion: the modified cells are given through a drip into a vein, usually over thirty to ninety minutes. The patient is watched closely during and immediately after.
- Step 6 - In-hospital monitoring: patients remain in or near the hospital for at least one to two weeks after infusion so that the team can detect and treat CRS or ICANS quickly if they occur.
Aftercare
Recovery after CAR-T therapy is a gradual process that requires close follow-up for months, because the most serious side effects can appear days or even weeks after the infusion.
- In-hospital stay: most patients remain in hospital or a supervised facility for at least one to two weeks after infusion, with daily blood tests and clinical checks
- Proximity to the treatment centre: after discharge, patients are usually asked to remain within a short distance of the hospital for a further four weeks, so that any sudden deterioration can be managed immediately
- Driving restrictions: patients are advised not to drive or operate heavy machinery for at least eight weeks after infusion, because of the risk of sudden neurological side effects
- Infection precautions: because immunity is reduced, patients are usually asked to avoid crowded places, wear a mask in public, and report any fever or signs of infection to the care team without delay
- Blood count monitoring: regular blood tests are needed for months to watch for prolonged low counts and to guide decisions about transfusions or growth factor injections
- Immunoglobulin replacement: if healthy B cells have been depleted, patients may receive regular infusions of immunoglobulin (infection-fighting proteins) to reduce infection risk
- Imaging follow-up: scans are repeated at defined intervals, often at one month, three months, and six months, to assess the cancer's response to treatment
- Neurological checks: the care team monitors cognition, speech, and coordination at each follow-up visit
- Vaccination: live vaccines are avoided for an extended period. The timing for resuming vaccinations is decided by the treating team based on immune recovery
- Lifestyle adjustments: a balanced diet, adequate rest, and avoiding smoking and alcohol support recovery, though specific guidance is provided by the care team
Cost & What Determines It
CAR-T cell therapy is one of the most expensive medical treatments available anywhere in the world, and the total cost varies enormously depending on where it is received, which product is used, and how complex the patient's case is.
- The CAR-T cell product itself: each batch is manufactured individually from the patient's own cells, and the commercial product licence fee alone accounts for a very large share of the total bill
- Disease complexity and prior treatment history: patients who have had multiple previous therapies or who have advanced disease often require more supportive care and longer hospital stays
- Hospital class and country: academic medical centres in North America, Europe, and certain parts of Asia charge substantially different rates for the same procedure, reflecting local labour costs, infrastructure, and regulatory fees
- Length of hospital stay: the mandatory post-infusion monitoring period, and any complications such as severe CRS or ICANS that require ICU admission, can add significantly to the total
- Leukapheresis (cell collection) procedure and associated equipment fees
- Lymphodepletion chemotherapy drugs and administration
- Specialist nursing, pharmacy, and laboratory fees during the monitoring period
- Imaging and pathology tests before, during, and after treatment
- Immunoglobulin replacement therapy if needed after treatment
- Bridging therapy: some patients need additional cancer treatment to keep the disease stable during the weeks the CAR-T product is being manufactured, and this is usually charged separately
Hospital packages for CAR-T therapy, where they exist, typically cover the cost of the CAR-T product, the infusion itself, and standard in-hospital monitoring. Items such as ICU care for severe complications, bridging therapy, long-term immunoglobulin replacement, and follow-up imaging at later intervals are usually billed separately and can add substantially to the total.
BPJS Kesehatan does not cover treatment received outside Indonesia, and most Indonesian private health insurance policies also exclude overseas care or cap reimbursement at levels far below the actual cost of CAR-T therapy. Patients who travel abroad for this treatment almost always pay entirely out of pocket or through international private health insurance that explicitly covers the procedure and country of treatment. Requesting a detailed written cost estimate from the hospital before travelling is the most reliable way to understand the full financial commitment and avoid unexpected bills.
Frequently Asked Questions
How many sessions of CAR-T cell therapy do I need?
CAR-T cell therapy is typically given as a single infusion, not a course of repeated sessions. Before that infusion, you go through a preparation phase called lymphodepletion (a short course of chemotherapy to make room for the new cells), and then a waiting period of a few weeks while your modified cells are grown in a laboratory. The full treatment journey, from the first blood collection to the infusion itself, usually takes several weeks in total.
What does CAR-T cell therapy feel like, and what side effects should I watch out for?
The infusion itself feels similar to a blood transfusion, but the days and weeks that follow can bring significant side effects that your medical team will watch closely. The most important one to know about is cytokine release syndrome, or CRS, which is when the immune system reacts very strongly and can cause high fever, low blood pressure, and breathing difficulties. Another possible effect is called ICANS (immune effector cell-associated neurotoxicity syndrome), which can cause confusion or difficulty speaking. Because of these risks, patients are usually kept in hospital for at least several weeks after the infusion so any reactions can be caught and treated early.
How soon will I know if CAR-T cell therapy is working?
Doctors usually assess how well the therapy has worked about one to three months after the infusion, using scans or blood tests depending on your condition. The modified CAR-T cells (immune cells that have been re-engineered to recognise and attack cancer cells) need time to expand and act inside the body, so results are not immediate. Your oncologist will set a follow-up schedule and explain what signs of response to look for in your individual case.
How much does CAR-T cell therapy cost?
The cost of CAR-T cell therapy varies considerably and depends on several factors specific to your situation. Key drivers include the type of cancer being treated, the particular CAR-T product recommended by your doctor, the length of your hospital stay for monitoring after the infusion, and the level of specialist nursing and intensive care involved. Because these factors combine differently for each patient, a written estimate from the treating hospital is the only reliable way to understand the actual cost for your case.
This page is general information, not a substitute for medical advice. Every case is different. Your doctor decides what is right for you.
